LY3410738   Click here for help

GtoPdb Ligand ID: 12340

Synonyms: example 2 [US11001596B2] | LY-3410738
Compound class: Synthetic organic
Comment: LY3410738 is a clinical stage orally bioactive, covalent mutant isocitrate dehydrogenase (IDH1) inhibitor [2]. It was developed for potential to treat cancers that are driven by the oncometabolite 2-hydroxyglutarate (2-HG) that is generated by mutated IDH1.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 90.9
Molecular weight 504.28
XLogP 3.84
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)N1CCN(CC1)[C@H](c1ccc(cc1)[C@@H](Nc1ncc2c(n1)N(CC)C(=O)OC2)C)CC1CC1
Isomeric SMILES CCN1c2nc(ncc2COC1=O)N[C@@H](C)c1ccc(cc1)[C@H](CC1CC1)N1CCN(CC1)C(=O)C=C
InChI InChI=1S/C28H36N6O3/c1-4-25(35)33-14-12-32(13-15-33)24(16-20-6-7-20)22-10-8-21(9-11-22)19(3)30-27-29-17-23-18-37-28(36)34(5-2)26(23)31-27/h4,8-11,17,19-20,24H,1,5-7,12-16,18H2,2-3H3,(H,29,30,31)/t19-,24-/m0/s1
InChI Key AFGYODUJVVOZAX-CYFREDJKSA-N
No information available.
Summary of Clinical Use Click here for help
LY3410738 has progressed to clinical evaluations in advanced solid tumours and hematologic malignancies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04521686 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Phase 1 Interventional Eli Lilly and Company
NCT04603001 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations Phase 1 Interventional Eli Lilly and Company